Discovery of a novel bromodomain and extra terminal domain (BET) protein inhibitor, I-BET282E, suitable for clinical progression

Katherine L. Jones, Dominic M. Beaumont, Sharon G. Bernard, Rino A. Bit, Simon P. Campbell, Chun-wa Chung, Leanne Cutler, Emmanuel H. Demont, Kate Dennis, Laurie Gordon, James R. Gray, Michael V. Haase, Antonia J. Lewis, Scott McCleary, Darren J. Mitchell, Susanne M. Moore, Nigel Parr, Olivia J. Robb, Nicholas Smithers, Peter E. SodenColin J. Suckling, Simon Taylor, Ann L. Walker, Robert J. Watson, Rab K. Prinjha

Research output: Contribution to journalArticlepeer-review

Abstract

The functions of the bromodomain and extra terminal (BET) family of proteins have been implicated in a wide range of diseases, particularly in the oncology and immuno-inflammatory areas, and several inhibitors are under investigation in the clinic. To mitigate the risk of attrition of these compounds due to structurally related toxicity findings, additional molecules from distinct chemical series were required. Here we describe the structure- and property-based optimization of the in vivo tool molecule I-BET151 toward I-BET282E, a molecule with properties suitable for progression into clinical studies.

Original languageEnglish
Pages (from-to)12200-12227
Number of pages28
JournalJournal of Medicinal Chemistry
Volume64
Issue number16
Early online date13 Aug 2021
DOIs
Publication statusPublished - 26 Aug 2021

Keywords

  • bromodomain
  • BET
  • protein inhibitors
  • extra terminal domain
  • proteins
  • oncology
  • immuno-inflammatory areas
  • clinical studies
  • peptides
  • rodent models
  • inhibitors
  • inhibition

Fingerprint

Dive into the research topics of 'Discovery of a novel bromodomain and extra terminal domain (BET) protein inhibitor, I-BET282E, suitable for clinical progression'. Together they form a unique fingerprint.

Cite this